KR101546977B1 - 근육 손실의 치료에서의 약물 조합 및 그것의 용도 - Google Patents

근육 손실의 치료에서의 약물 조합 및 그것의 용도 Download PDF

Info

Publication number
KR101546977B1
KR101546977B1 KR1020097024247A KR20097024247A KR101546977B1 KR 101546977 B1 KR101546977 B1 KR 101546977B1 KR 1020097024247 A KR1020097024247 A KR 1020097024247A KR 20097024247 A KR20097024247 A KR 20097024247A KR 101546977 B1 KR101546977 B1 KR 101546977B1
Authority
KR
South Korea
Prior art keywords
delete delete
formoterol
treatment
product
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097024247A
Other languages
English (en)
Korean (ko)
Other versions
KR20100017205A (ko
Inventor
줄리안 클리브 길버트
로버트 윌리암 그리스트우드
Original Assignee
아카시아 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by 아카시아 파마 리미티드 filed Critical 아카시아 파마 리미티드
Publication of KR20100017205A publication Critical patent/KR20100017205A/ko
Application granted granted Critical
Publication of KR101546977B1 publication Critical patent/KR101546977B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
KR1020097024247A 2007-04-24 2008-04-24 근육 손실의 치료에서의 약물 조합 및 그것의 용도 Expired - Fee Related KR101546977B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0707931.2 2007-04-24
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0707930.4 2007-04-24
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
GB0710101.7 2007-05-25

Publications (2)

Publication Number Publication Date
KR20100017205A KR20100017205A (ko) 2010-02-16
KR101546977B1 true KR101546977B1 (ko) 2015-08-24

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097024247A Expired - Fee Related KR101546977B1 (ko) 2007-04-24 2008-04-24 근육 손실의 치료에서의 약물 조합 및 그것의 용도

Country Status (16)

Country Link
US (1) US8653052B2 (https=)
EP (1) EP2155180B1 (https=)
JP (1) JP5627452B2 (https=)
KR (1) KR101546977B1 (https=)
CN (2) CN104306381A (https=)
AU (1) AU2008240379B2 (https=)
BR (1) BRPI0810461A2 (https=)
CA (1) CA2721739C (https=)
DK (1) DK2155180T3 (https=)
EA (1) EA018918B1 (https=)
ES (1) ES2592289T3 (https=)
HK (1) HK1202262A1 (https=)
IL (1) IL201426A (https=)
MX (1) MX2009011294A (https=)
NZ (1) NZ580975A (https=)
WO (1) WO2008129308A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
US9597531B2 (en) * 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
NZ790678A (en) * 2020-01-13 2026-01-30 Astromedical Biotechnology Ltd Use of ketamine in the treatment of cachexia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
ATE539737T1 (de) * 2002-04-12 2012-01-15 Alkermes Pharma Ireland Ltd Nanopartikuläre megestrol- formulierungen
ES2245612B1 (es) * 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
WO2008093148A2 (en) * 2005-12-22 2008-08-07 Anaborex, Inc. Compositions and methods for prevention and treatment of cachexia
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. P. Finley, Detection and management of cachexia in cancer patients, Advanced studies in nursing, 2003, Vol.1, No.1, pp. 8-12*
S. Busquets et al, Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting, Cancer Research, 2004, Vol.64, pp. 6725-6731*
Schmoll E et al, Megestrol acetate in cancer cachexia, Semin Oncol., 1991, Vol. 18(1 Suppl 2), pp. 32-34(영문 초록)*

Also Published As

Publication number Publication date
NZ580975A (en) 2012-10-26
IL201426A0 (en) 2010-05-31
AU2008240379B2 (en) 2012-10-04
EA200970957A1 (ru) 2010-04-30
CA2721739A1 (en) 2008-10-30
US20100130456A1 (en) 2010-05-27
HK1202262A1 (en) 2015-09-25
EA018918B1 (ru) 2013-11-29
ES2592289T3 (es) 2016-11-29
CA2721739C (en) 2016-08-23
AU2008240379A1 (en) 2008-10-30
IL201426A (en) 2016-09-29
WO2008129308A3 (en) 2009-12-17
MX2009011294A (es) 2010-01-29
US8653052B2 (en) 2014-02-18
CN104306381A (zh) 2015-01-28
KR20100017205A (ko) 2010-02-16
WO2008129308A2 (en) 2008-10-30
EP2155180B1 (en) 2016-07-13
EP2155180A2 (en) 2010-02-24
BRPI0810461A2 (pt) 2014-10-14
CN101730547A (zh) 2010-06-09
JP5627452B2 (ja) 2014-11-19
JP2010525044A (ja) 2010-07-22
DK2155180T3 (en) 2016-09-12

Similar Documents

Publication Publication Date Title
KR101546977B1 (ko) 근육 손실의 치료에서의 약물 조합 및 그것의 용도
TWI434688B (zh) 選擇性ｓ１ｐ1受體激動劑之投藥療程
JP5271918B2 (ja) メタボリック症候群治療用の新規組成物
JP2021527092A5 (https=)
CN108289960A (zh) Ep4受体拮抗剂用于治疗nash相关肝癌的用途
TW202333729A (zh) 組合
JPWO2019241442A5 (https=)
EP3675845B1 (en) Novel gamma aminobutyric acid type a receptor modulators for mood disorders
TWI501763B (zh) Hepatocellular carcinoma is treated with a relapse after treatment
KR102266696B1 (ko) 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
JP2019505555A (ja) がん治療における抗エストロゲン剤有効性の増強のための擬絶食の使用
WO2022040512A1 (en) Combinational drug anticancer therapies
HK1144555A (en) Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
JP5469779B2 (ja) 多発性骨髄腫の治療のための組成物および方法
CN111374972A (zh) 双环醇在治疗肥胖以及相关的代谢性疾病中的应用
WO2023212812A1 (en) Method and use of psilocybin in the prevention and treatment of stroke
CN113015558A (zh) 用于治疗酒精使用障碍的试剂
RU2009115833A (ru) Препараты для лечения жировой ткани, кожной ткани и расстройств и мышечной ткани
HK1180954A (en) Medicinal agent for prevention and/or treatment of hepatocellular carcinoma
WO2011156901A2 (en) Compounds, compositions and methods for treatment of multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180819

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180819